Microbot Medical Inc. (MBOT): History, Ownership, Mission, How It Works & Makes Money

Microbot Medical Inc. (MBOT) is betting its entire future on whether a single-use, remotely operated robotic system can truly disrupt the $15 billion endovascular surgery market, but are they finally transitioning from a research-stage company to a commercial one?

You need to look past the current financial reality-a nine-month net loss of $9.68 million through September 30, 2025-and focus on the commercial pivot: the company commenced the Limited Market Release of its flagship LIBERTY® Endovascular Robotic System in the U.S. in November 2025, aiming to capitalize on a technology that recently achieved 100% robotic navigation success in a pivotal trial.

With a robust current ratio of 12.1 providing a solid liquidity cushion, and analysts projecting a potential 2025 revenue of up to $6 million from what has historically been zero, the real question is whether this innovative micro-robot can democratize complex procedures and deliver value beyond its current $142 million market capitalization.

Microbot Medical Inc. (MBOT) History

You're looking for the bedrock of Microbot Medical Inc., the story behind the ticker MBOT, and honestly, it's a classic med-tech evolution: a long development phase punctuated by recent, critical regulatory wins. The company has transformed from an Israeli-based micro-robotics research firm into a commercial-stage player in the U.S. endovascular space, a shift that fundamentally changes its risk profile.

Microbot Medical Inc.'s Founding Timeline

Microbot Medical's origins trace back to the late 1980s in Israel, though its modern corporate structure and focus on endovascular robotics crystalized much later. This long-term research foundation is what underpins their current intellectual property (IP).

Year established

The company was originally founded in 1988, though a significant corporate restructuring or re-establishment is sometimes cited around 2010.

Original location

The initial location was Nesher, Israel, a hub for its foundational research and development. The current headquarters is in Hingham, Massachusetts, USA.

Founding team members

The company was founded by a team of pioneers in robotics: Harel Gadot (now CEO and Chairman), Moshe Shoham, and Yosseph Bornstein.

Initial capital/funding

Specific initial seed capital is undisclosed, but a major early capital injection came from the Initial Public Offering (IPO) in 2016, which raised $16.1 million. More recently, the company secured a post-IPO funding round of $13 million on January 7, 2025.

Microbot Medical Inc.'s Evolution Milestones

The company's history is a clear march toward commercialization, marked by strategic acquisitions, key regulatory approvals, and significant capital raises to fund the development of its flagship LIBERTY Endovascular Robotic System.

Microbot Medical Inc.'s Transformative Moments

The biggest shift for Microbot Medical was defintely in 2025, moving from a pure R&D story to a commercial one. This transition required a major capital infusion and a complete overhaul of the operational focus, moving from lab to logistics.

The September 2025 FDA 510(k) clearance for the LIBERTY Endovascular Robotic System is the defining moment. This clearance positions the company to target an initial U.S. market of approximately 2.5 million peripheral endovascular procedures annually. That's a huge market to unlock.

• Commercial Launch Shift: The company immediately initiated a Limited Market Release in Q4 2025 in selected high-volume regions, supported by a new U.S.-based third-party logistics (3PL) partner to manage inventory and distribution.
• Strategic Capital Raise: Following the FDA clearance, the company announced plans to raise up to US$92.2 million in gross proceeds through preferred investment options, providing the necessary runway to fund the commercialization ramp-up.
• Clinical Validation: The pivotal clinical trial for LIBERTY showed 100% success in robotic navigation to the target vessel and a 92% reduction in physician radiation exposure. This safety and efficacy data is a critical sales tool.

Here's the quick math: as of the end of Q3 2025, the company reported a net loss of $3.58 million for the quarter, reflecting the heavy R&D and commercial preparation costs. Still, they ended September 2025 with a strong cash and investments balance of $80.2 million, giving them ample liquidity to execute the launch. You can dive deeper into the ownership dynamics and institutional interest in Exploring Microbot Medical Inc. (MBOT) Investor Profile: Who's Buying and Why?

Microbot Medical Inc. (MBOT) Ownership Structure

Microbot Medical Inc. is a publicly traded company, so its ownership is distributed among institutional funds, company insiders, and the general public, creating a structure where no single entity holds a majority controlling stake.

This distribution means that while institutional investors like Vanguard Group Inc. and BlackRock Inc. influence the stock price through large-volume trading, the company's strategic direction is heavily guided by its co-founders and executive team who hold a significant insider stake.

Microbot Medical Inc.'s Current Status

Microbot Medical Inc. is a Public company, trading on the Nasdaq Capital Market under the ticker symbol MBOT. This public status means its financials and governance are subject to SEC regulations, providing transparency for investors.

As of November 2025, the company's market capitalization stood at approximately $142 million, with the stock price trading around $1.73 per share on November 20, 2025. The company has been actively raising capital through offerings in 2025, including a registered direct offering and concurrent private placement in January 2025 that generated approximately $8.6 million in gross proceeds. If you want to dive deeper into their strategic goals, you can review their Mission Statement, Vision, & Core Values of Microbot Medical Inc. (MBOT).

Microbot Medical Inc.'s Ownership Breakdown

The company's ownership structure, as of October 2025, shows a notable concentration among insiders, which is common for emerging medical technology firms. Honestly, a high insider ownership percentage suggests management's interests are defintely aligned with long-term shareholder value.

Here's the quick math on who controls the shares:

Microbot Medical Inc.'s Leadership

The company's strategy is steered by its co-founder and a growing commercial team, reflecting its shift toward potential commercialization of the LIBERTY® Endovascular Robotic System.

• Harel Gadot serves as the Co-Founder, Chief Executive Officer (CEO), President, and Chairman of the Board, providing unified strategic and operational leadership.
• The leadership team was bolstered in April 2025 with the addition of key commercial roles, preparing for the anticipated U.S. launch.
• Allison Rosefort joined as Vice President of Marketing in April 2025, focusing on downstream marketing and brand management.
• Paul Mullen is the Vice President of Sales, a critical role for establishing the U.S. commercial readiness infrastructure.

The co-founders, including Harel Gadot, Moshe Shoham, and Yossi Bornstein, remain influential in the company's direction, holding significant intellectual property and institutional knowledge.

Next step: Review the latest SEC filings for any new executive appointments.

Microbot Medical Inc. (MBOT) Mission and Values

Microbot Medical Inc. is a pre-commercial stage medical technology company dedicated to transforming endovascular procedures by making advanced robotic surgery more accessible and precise. Its core purpose centers on innovation and patient care, aiming to eliminate the high capital cost barriers that limit access to life-saving robotic interventions.

Microbot Medical Inc.'s Core Purpose

The company's commitment goes beyond technology; it's about redefining care through accessibility and safety. This is a crucial distinction, especially when you look at the financials: the company's TTM Research & Development (R&D) spending was approximately $7.39 million as of June 2025, which shows a significant investment in its mission, even before its projected 2025 Net Sales forecast of $5.63 million. Here's the quick math: R&D is currently outstripping sales, which is typical for a pre-commercial firm focused on a high-barrier-to-entry product like the LIBERTY Endovascular Robotic System.

Official mission statement

While an explicit, single-sentence mission statement isn't widely published, Microbot Medical Inc.'s mission is to transform the landscape of robotic surgery through innovative solutions. The focus is on developing and commercializing micro-robotic technologies to improve patient outcomes and enhance surgical precision. Exploring Microbot Medical Inc. (MBOT) Investor Profile: Who's Buying and Why?

• Develop advanced micro-robotic surgical tools.
• Improve the precision, safety, and efficiency of procedures.
• Enhance patient outcomes via minimally invasive technologies.

Vision statement

Microbot Medical Inc.'s vision is to redefine endovascular robotics and improve the quality of care for millions of patients and providers globally. They envision a future where complex surgeries are defintely performed with greater accuracy and less invasiveness, which translates to quicker recovery times.

• Create a new medical robotic category.
• Become a market leader in micro-robotic surgery.
• Establish a new standard of care through innovation.

The company is not just building a robot; it is building an accessible platform. This is a big deal.

Microbot Medical Inc. slogan/tagline

The company does not use a single, formal slogan, but its brand messaging is clearly anchored in the concept of expanding access to care. The core message is best summarized by the phrase:

• Breaking Down Barriers to Access.

This tagline highlights the key differentiator of their LIBERTY System: it's the world's first single-use, fully disposable endovascular robotic system, which aims to eliminate the need for expensive capital equipment and dedicated Cath-lab rooms. This approach directly supports their stated core values of innovation, trust, and proven results, plus a shared commitment to patients and physician safety.

Microbot Medical Inc. (MBOT) How It Works

Microbot Medical Inc. is transforming endovascular procedures-minimally invasive surgeries inside blood vessels-by commercializing the world's first single-use, remotely operated robotic system. The company's model works by shifting the cost burden from a massive upfront hospital capital expense (CAPEX) to a predictable, per-procedure operating expense (OPEX), which dramatically lowers the barrier to adopting advanced robotics.

You need to understand that their value proposition is simple: better precision for the surgeon and a disposable system that eliminates the financial and logistical headaches of traditional robotic platforms. For the 2025 fiscal year, analysts project Microbot Medical will generate revenue in the range of $3.1 million to $6 million as the limited market release gains traction.

Microbot Medical Inc.'s Product/Service Portfolio

Microbot Medical Inc.'s Operational Framework

The core of Microbot Medical's operation is a lean, outsourced commercialization and manufacturing model centered on the disposable LIBERTY® system, which received FDA 510(k) clearance in September 2025. They don't build expensive capital equipment inventory; they focus on the high-margin, recurring revenue consumable. This is defintely a smart way to start.

Value creation is driven by three key processes:

• R&D and IP Expansion: Continual investment in technology, evidenced by a 75.56% increase in R&D expenses in 2024, to broaden the system's application beyond peripheral procedures.
• Asset-Light Commercialization: Utilizing a U.S.-based third-party logistics (3PL) partner for integrated fulfillment, order processing, and inventory maintenance, eliminating the need for Microbot Medical to build its own dedicated field service or warehouse infrastructure.
• Financial Fortification: Securing capital to fund the commercial launch, including the approximately $25.2 million raised from the first closing of a preferred investment options exercise in September 2025, plus a non-dilutive grant of NIS 2.15 Million (about $630,000) from the Israel Innovation Authority.

Here's the quick math on their burn: Total Operating Expenses were $13.47 million for the trailing twelve months ending June 30, 2025, so the recent capital raise is crucial for sustaining the commercial ramp-up. You can dive deeper into the financial picture here: Breaking Down Microbot Medical Inc. (MBOT) Financial Health: Key Insights for Investors

Microbot Medical Inc.'s Strategic Advantages

Microbot Medical's success hinges on its ability to leverage its first-mover status in a niche, high-growth segment of the surgical robotics market. Their advantages are structural, not just technological.

• Disruptive Business Model: The single-use design eliminates the customer's need for a large Capital Expenditure (CAPEX) approval, allowing the purchase to be made from the Operational Expense (OPEX) budget, which significantly expedites the purchasing decision.
• First-to-Market FDA Clearance: Being the first FDA-cleared single-use, remotely operated robotic system for peripheral endovascular procedures gives them an early lead in a U.S. market of approximately 2.5 million annual procedures.
• Robust Intellectual Property (IP): A growing global IP portfolio, including recent patent grants in Japan, the U.S., China, and Israel, protects their core technology and limits direct competition in key markets.
• Physician Safety and Ergonomics: The remote operation capability allows physicians to perform procedures away from the harmful primary X-ray beam, addressing a critical, long-standing occupational hazard for interventionalists.

Microbot Medical Inc. (MBOT) How It Makes Money

Microbot Medical Inc. makes money by monetizing its intellectual property and development pipeline, primarily through non-dilutive grants, strategic collaboration agreements, and interest income on its substantial cash reserves, as it transitions into a commercial-stage company with the launch of its LIBERTY® Endovascular Robotic System.

The company's financial model is currently that of a high-growth, pre-commercial medical device developer, meaning revenue from operations is minimal, and the focus is on funding research and development (R&D) to secure future product sales. For the full 2025 fiscal year, analyst consensus projects total revenue of approximately $5.63 million.

Microbot Medical Inc.'s Revenue Breakdown

The company's revenue profile for the 2025 fiscal year is heavily skewed toward non-product sources, reflecting its stage of commercialization. The Limited Market Release (LMR) of the LIBERTY® System, which began in November 2025, represents the initial, small-scale product sales stream.

Here's the quick math for the projected $5.63 million in FY 2025 revenue:

The largest portion, 87.0%, is categorized as Collaboration and Interest Income. This is typical for a development-stage company with a large cash balance, generating significant interest income from investments, plus revenue from any early R&D partnerships or licensing deals.

The 11.2% from Non-Dilutive Grant Funding is anchored by sources like the Israel Innovation Authority (IIA), which approved a grant of approximately $630,000 in August 2025 to bolster manufacturing capabilities for the LIBERTY® System. This funding is defintely a key non-dilutive source.

The 1.8% from Product Sales is the most critical to watch; it represents the very beginning of the commercial ramp-up with the LIBERTY® Endovascular Robotic System LMR. This percentage is small now, but it is the future of the business model and is expected to grow rapidly once the Full Market Release occurs in April 2026.

Business Economics

The core economic engine for Microbot Medical Inc. is the shift from high capital expenditure (CapEx) to a per-procedure operational expenditure (OpEx) model for hospitals.

• Disposable Model: The LIBERTY® System is the first FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures. This eliminates the need for hospitals to spend millions on a large, fixed-base robotic system.
• Pricing Strategy: Management is expected to price the disposable system aggressively to facilitate market uptake. The low barrier to entry is designed to quickly capture a share of the approximately 2.5 million peripheral endovascular procedures performed annually in the U.S.
• Gross Margin Potential: While no 2025 gross margin is public, the long-term profitability hinges on the high-volume manufacturing of the disposable component. Once production scales, the gross margin on the single-use device sales should be high, which is the standard for successful disposable medical device companies.
• Cost Structure: The current cost structure is dominated by R&D, with trailing twelve-month (TTM) R&D expenses as of June 2025 sitting at $7.39 million. [cite: 14 from previous step] This is the cost of building the future revenue stream.

Microbot Medical Inc.'s Financial Performance

As of November 2025, the company's financial health is defined by its strong liquidity and significant investment in future growth, typical of a company just entering commercialization.

• Cash Position: The company ended September 2025 with a strong cash and investments balance of $80.2 million, providing a long runway to fund the LIBERTY® System's full commercial launch.
• Net Loss: For the third quarter of 2025, Microbot Medical reported a net loss of $3.6 million, or $0.07 per share, slightly exceeding analyst loss estimates. The trailing 12-month net loss is approximately $13.1 million as of September 30, 2025.
• Cash Burn: Cash flows from operating activities were negative $3.8 million in Q3 2025, which reflects the ongoing investment in R&D and the initial build-out of the commercial infrastructure (like hiring the core commercial team and establishing logistics).
• Liquidity: The company holds more cash than debt and has an impressive current ratio of 27.53 as of September 2025, indicating very strong short-term liquidity.

This financial picture shows a company burning cash to fund an imminent commercial launch but with a substantial cash reserve to manage that burn. To get a deeper understanding of the institutional confidence in this strategy, you should be Exploring Microbot Medical Inc. (MBOT) Investor Profile: Who's Buying and Why?

Microbot Medical Inc. (MBOT) Market Position & Future Outlook

Microbot Medical Inc. is a high-risk, high-reward proposition right now, moving from a pre-revenue R&D phase into its critical commercialization stage. The company's future hinges on the successful, scalable adoption of its LIBERTY Endovascular Robotic System, which is currently in a limited U.S. market release as of November 2025.

This system, the first FDA-cleared, single-use, remotely operated robotic solution for peripheral endovascular procedures, is the key to unlocking a U.S. addressable market of approximately 2.5 million procedures annually. You need to watch the transition from this initial market release to the planned full commercial launch in April 2026; that's the defintely next major catalyst.

Competitive Landscape

In the surgical robotics space, Microbot Medical is the ultimate David facing the Goliaths. While the broader market is dominated by multi-billion dollar systems, Microbot is carving out a niche in the endovascular segment with a fundamentally different, disposable model. Here's how the landscape looks as of late 2025, focusing on the key players in surgical robotics:

Opportunities & Challenges

The core opportunity for Microbot Medical is to democratize robotic surgery, but that ambition is shadowed by immense execution risk. You're looking at a classic high-growth potential scenario that requires perfect operational scaling. What this estimate hides is the time it takes to change entrenched surgical habits.

Industry Position

Microbot Medical is positioned as a disruptive challenger, not an incumbent. Their market position is currently defined by their pipeline and intellectual property, not by revenue, which is essentially $0.0 for the trailing twelve months ending June 30, 2025. They are a small-cap company with a market capitalization of around $142 million as of November 2025, which is tiny compared to the multi-billion dollar valuations of their main competitors.

The company's strength lies in its balance sheet liquidity, which buys them time to execute. They closed Q3 2025 with a strong cash and investments balance of $80.2 million, giving them a current ratio of 27.53. This cash runway is crucial for funding the full commercial launch and navigating the inevitable initial losses. For a deeper dive into how they are managing that cash burn, check out Breaking Down Microbot Medical Inc. (MBOT) Financial Health: Key Insights for Investors.

• Niche Focus: Targeting peripheral endovascular procedures, a segment where traditional large robotic systems are less prevalent.
• Technology Edge: The remote operation feature is a significant safety and efficiency advantage, removing the physician from direct radiation exposure.
• Financial Reality: Despite the technology, they are a development-stage company; the Q3 2025 net loss was $3.6 million, a clear sign that the commercial ramp-up is expensive.

So, the company is in a race: burn rate versus market adoption. Their success depends entirely on how quickly hospitals adopt the LIBERTY system over the next 18 months.